Sanguedolce Francesca, Russo Davide, Mancini Vito, Selvaggio Oscar, Calo Beppe, Carrieri Giuseppe, Cormio Luigi
Department of Pathology, University Hospital, I-71121 Foggia, Italy.
Department of Urology and Renal Transplantation, University Hospital, I-71121 Foggia, Italy.
Mol Clin Oncol. 2019 Feb;10(2):205-213. doi: 10.3892/mco.2018.1786. Epub 2018 Dec 7.
Micropapillary carcinoma of the bladder (MPBC) is a variant type of infiltrating urothelial carcinoma, which portends a poor biological behavior in terms of disease stage at first diagnosis and clinical outcome; its peculiar morphology raises issues concerning the ability of tumor detection by imaging techniques and proper biopsy procedure, and the appropriate treatment for non-muscle infiltrating and muscle-infiltrating MPBC remains a matter of debate. On the basis of its established prognostic and therapeutic role in breast and gastro-esophageal cancer in the first instance, the human epidermal growth factor receptor-2 (HER2) has been investigated in selected case series of MPBC over the last 10 years. The aim of the present review was to summarize the existing evidence on HER2 status in MPBC, and to discuss its present and future utility in risk assessment and treatment choice of this uncommon, yet aggressive, disease.
膀胱微乳头癌(MPBC)是浸润性尿路上皮癌的一种变异类型,就初次诊断时的疾病分期和临床结果而言,其生物学行为较差;其独特的形态引发了关于通过成像技术进行肿瘤检测的能力以及适当活检程序的问题,并且对于非肌层浸润性和肌层浸润性MPBC的适当治疗仍存在争议。基于人表皮生长因子受体2(HER2)最初在乳腺癌和胃食管癌中已确立的预后和治疗作用,在过去10年中,已在选定的MPBC病例系列中对其进行了研究。本综述的目的是总结关于MPBC中HER2状态的现有证据,并讨论其在这种罕见但侵袭性疾病的风险评估和治疗选择中的当前及未来效用。